QIAGEN N.V. commences an Equity Buyback Plan for 20,660,523 shares, representing 8.95% of its issued share capital, under the authorization approved on June 29, 2021.
July 20, 2021 at 02:05 am EDT
Share
QIAGEN N.V. (NYSE:QGEN) commences a share repurchases on July 2021, under the program mandated by the shareholders in the Annual General Meeting held on June 29, 2021. As per the mandate, the company is authorized to repurchase up to 20,660,523 shares, representing 8.95% of its issued share capital, such that the company or any subsidiary of the company shall not hold more than 10% of its issued share capital at any time. The share repurchases may occur at a price between €0.01 and 110% of the higher of the average closing price of the company's shares on the New York Stock Exchange or, as applicable, the Frankfurt Stock Exchange, for the five trading days prior to the day of purchase or with respect to preference and finance preference shares, at a price between €0.01 and three times the issuance price. The authorization will be valid for a period of 18 months, until December 29, 2022. As of May 7, 2021, the company had 230,829,308.67 shares in issue and 2,422,408.33 shares in treasury.
On July 12, 2021, the company announced a share repurchase program. Under the program, the company will repurchase up to 2,100,000 shares for $100 million worth of its shares. The program will run between July 20, 2021, until September 17, 2021.
On September 22, 2021, the company announced that it will initiate the repurchase of a second tranche of shares under the share repurchase program that was announced by an ad-hoc announcement on July 12, 2021. Under the program, the company will repurchase up to 350,000 shares for $19.4 million. The program will run between September 27, 2021, until October 29, 2021.
Qiagen NV is a holding company based in the Netherlands. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials. Its assay technologies make these biomolecules visible for analysis, such as identifying the genetic information of a pathogen or a gene mutation in a tumor. Its bioinformatics solutions interpret data to provide actionable insights. The Company's automation platforms based on polymerase chain reaction (PCR), next-generation sequencing (NGS) and other technologies tie these together in molecular testing workflows from Sample to Insight.
QIAGEN N.V. commences an Equity Buyback Plan for 20,660,523 shares, representing 8.95% of its issued share capital, under the authorization approved on June 29, 2021.
QIAGEN N.V. 
